416 related articles for article (PubMed ID: 34056991)
21. ST-Producing E. coli Oppose Carcinogen-Induced Colorectal Tumorigenesis in Mice.
Li P; Lin JE; Snook AE; Waldman SA
Toxins (Basel); 2017 Sep; 9(9):. PubMed ID: 28895923
[TBL] [Abstract][Full Text] [Related]
22. The hormone receptor GUCY2C suppresses intestinal tumor formation by inhibiting AKT signaling.
Lin JE; Li P; Snook AE; Schulz S; Dasgupta A; Hyslop TM; Gibbons AV; Marszlowicz G; Pitari GM; Waldman SA
Gastroenterology; 2010 Jan; 138(1):241-54. PubMed ID: 19737566
[TBL] [Abstract][Full Text] [Related]
23. Silencing the GUCA2A-GUCY2C tumor suppressor axis in CIN, serrated, and MSI colorectal neoplasia.
Bashir B; Merlino DJ; Rappaport JA; Gnass E; Palazzo JP; Feng Y; Fearon ER; Snook AE; Waldman SA
Hum Pathol; 2019 May; 87():103-114. PubMed ID: 30716341
[TBL] [Abstract][Full Text] [Related]
24. GUCY2C as a biomarker to target precision therapies for patients with colorectal cancer.
Lisby AN; Flickinger JC; Bashir B; Weindorfer M; Shelukar S; Crutcher M; Snook AE; Waldman SA
Expert Rev Precis Med Drug Dev; 2021; 6(2):117-129. PubMed ID: 34027103
[TBL] [Abstract][Full Text] [Related]
25. GUCY2C Signaling Opposes the Acute Radiation-Induced GI Syndrome.
Li P; Wuthrick E; Rappaport JA; Kraft C; Lin JE; Marszalowicz G; Snook AE; Zhan T; Hyslop TM; Waldman SA
Cancer Res; 2017 Sep; 77(18):5095-5106. PubMed ID: 28916678
[TBL] [Abstract][Full Text] [Related]
26. Guanylyl cyclase C ameliorates visceral pain: an unsuspected link.
Liddle RA
J Clin Invest; 2023 Feb; 133(4):. PubMed ID: 36787251
[TBL] [Abstract][Full Text] [Related]
27. A uroguanylin-GUCY2C endocrine axis regulates feeding in mice.
Valentino MA; Lin JE; Snook AE; Li P; Kim GW; Marszalowicz G; Magee MS; Hyslop T; Schulz S; Waldman SA
J Clin Invest; 2011 Sep; 121(9):3578-88. PubMed ID: 21865642
[TBL] [Abstract][Full Text] [Related]
28. GUCY2C: at the intersection of obesity and cancer.
Kim GW; Lin JE; Waldman SA
Trends Endocrinol Metab; 2013 Apr; 24(4):165-73. PubMed ID: 23375388
[TBL] [Abstract][Full Text] [Related]
29. Molecular insights into recognition of GUCY2C by T-cell engaging bispecific antibody anti-GUCY2CxCD3.
Rampuria P; Mosyak L; Root AR; Svenson K; Agostino MJ; LaVallie ER
Sci Rep; 2023 Aug; 13(1):13408. PubMed ID: 37591971
[TBL] [Abstract][Full Text] [Related]
30. Preclinical Evaluation of a Replication-Deficient Recombinant Adenovirus Serotype 5 Vaccine Expressing Guanylate Cyclase C and the PADRE T-helper Epitope.
Snook AE; Baybutt TR; Hyslop T; Waldman SA
Hum Gene Ther Methods; 2016 Dec; 27(6):238-250. PubMed ID: 27903079
[TBL] [Abstract][Full Text] [Related]
31. Tumor radiation therapy creates therapeutic vaccine responses to the colorectal cancer antigen GUCY2C.
Witek M; Blomain ES; Magee MS; Xiang B; Waldman SA; Snook AE
Int J Radiat Oncol Biol Phys; 2014 Apr; 88(5):1188-95. PubMed ID: 24661671
[TBL] [Abstract][Full Text] [Related]
32. Obesity-Induced Colorectal Cancer Is Driven by Caloric Silencing of the Guanylin-GUCY2C Paracrine Signaling Axis.
Lin JE; Colon-Gonzalez F; Blomain E; Kim GW; Aing A; Stoecker B; Rock J; Snook AE; Zhan T; Hyslop TM; Tomczak M; Blumberg RS; Waldman SA
Cancer Res; 2016 Jan; 76(2):339-46. PubMed ID: 26773096
[TBL] [Abstract][Full Text] [Related]
33. T-Cell Responses to Immunodominant Listeria Epitopes Limit Vaccine-Directed Responses to the Colorectal Cancer Antigen, Guanylyl Cyclase C.
Flickinger JC; Singh J; Yarman Y; Carlson RD; Barton JR; Waldman SA; Snook AE
Front Immunol; 2022; 13():855759. PubMed ID: 35355987
[TBL] [Abstract][Full Text] [Related]
34. The paracrine hormone for the GUCY2C tumor suppressor, guanylin, is universally lost in colorectal cancer.
Wilson C; Lin JE; Li P; Snook AE; Gong J; Sato T; Liu C; Girondo MA; Rui H; Hyslop T; Waldman SA
Cancer Epidemiol Biomarkers Prev; 2014 Nov; 23(11):2328-37. PubMed ID: 25304930
[TBL] [Abstract][Full Text] [Related]
35. Gut-associated cGMP mediates colitis and dysbiosis in a mouse model of an activating mutation in GUCY2C.
Mishra V; Bose A; Kiran S; Banerjee S; Shah IA; Chaukimath P; Reshi MM; Srinivas S; Barman A; Visweswariah SS
J Exp Med; 2021 Nov; 218(11):. PubMed ID: 34546338
[TBL] [Abstract][Full Text] [Related]
36. GUCY2C-directed CAR-T cells oppose colorectal cancer metastases without autoimmunity.
Magee MS; Kraft CL; Abraham TS; Baybutt TR; Marszalowicz GP; Li P; Waldman SA; Snook AE
Oncoimmunology; 2016; 5(10):e1227897. PubMed ID: 27853651
[TBL] [Abstract][Full Text] [Related]
37. Translating colorectal cancer prevention through the guanylyl cyclase C signaling axis.
Blomain ES; Lin JE; Kraft CL; Trela UT; Rock JM; Aing AS; Snook AE; Waldman SA
Expert Rev Clin Pharmacol; 2013 Sep; 6(5):557-64. PubMed ID: 23971873
[TBL] [Abstract][Full Text] [Related]
38. Consistent expression of guanylyl cyclase-C in primary and metastatic gastrointestinal cancers.
Danaee H; Kalebic T; Wyant T; Fassan M; Mescoli C; Gao F; Trepicchio WL; Rugge M
PLoS One; 2017; 12(12):e0189953. PubMed ID: 29261789
[TBL] [Abstract][Full Text] [Related]
39. Meconium ileus caused by mutations in GUCY2C, encoding the CFTR-activating guanylate cyclase 2C.
Romi H; Cohen I; Landau D; Alkrinawi S; Yerushalmi B; Hershkovitz R; Newman-Heiman N; Cutting GR; Ofir R; Sivan S; Birk OS
Am J Hum Genet; 2012 May; 90(5):893-9. PubMed ID: 22521417
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of plecanatide in treating constipation predominant irritable bowel syndrome.
Miner PB
Expert Opin Pharmacother; 2018 Feb; 19(2):177-183. PubMed ID: 29376436
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
